AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06118034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
Trial: NCT05225415
Drug: CT1812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered CT1812
Trial: NCT05996185
Drug: DA-EPOCH Protocol
RxNorm normalized name: Epoch Blemish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
Trial: NCT06577558
Drug: SR1375 capsule 0.3mg+regular treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR1375 capsule 0.3mg QD orally+CAP regular treatments
Trial: NCT06577558
Drug: Placebo capsule+regular treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule QD orally+CAP regular treatments
Trial: NCT05071118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
Trial: NCT05028218
Drug: TQB3824 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
Trial: NCT06176196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT04712279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo q.d.for 05 days
Trial: NCT06744400
Drug: Grafalon® administered during 5 consecutive days at 1 mg/kg/j
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation.
Trial: NCT06764862
Drug: HSK44459 dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Trial: NCT06764862
Drug: HSK44459 dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Trial: NCT06764862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Trial: NCT06531499
Drug: AAA617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
Trial: NCT06531499
Drug: Gonadotropin-releasing hormone (GnRH) analogues
RxNorm normalized name: Gonadotropin releasing hormone analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE
Trial: NCT06054321
Drug: antidepressant monotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
Trial: NCT06702124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration for 24 weeks
Trial: NCT05899816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT06379217
Drug: [68Ga]Ga-PSMA-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)
Trial: NCT06379217
Drug: [68Ga]GA-DOTA-TATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
Trial: NCT06379217
Drug: [68Ga]Ga-NeoB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).
Trial: NCT06379217
Drug: [177Lu]Lu-PSMA-617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.
Trial: NCT06379217
Drug: [177Lu]Lu-DOTA-TATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.
Trial: NCT06379217
Drug: [177Lu]Lu-NeoB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles
Trial: NCT06379217
Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)
Trial: NCT06379217
Drug: Gonadotropin-releasing hormone (GnRH) analogues
RxNorm normalized name: Gonadotropin releasing hormone analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE
Trial: NCT06734234
Drug: GSK4771261
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4771261 will be administered.
Trial: NCT06734234
Drug: Placebo matching GSK4771261
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK4771261 will be administered.
Trial: NCT06105528
Drug: PMN310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute intravenous infusion
Trial: NCT06105528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute intravenous infusion
Trial: NCT05566795
Drug: Chemotherapeutic Agent
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution for injection
Trial: NCT05410860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Trial: NCT06651567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
Trial: NCT04846881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06789302
Drug: DT2-SCT intravenous infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.~The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects.
Trial: NCT06790823
Drug: The probiotic supplement (Moodamin capsuls)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.
Trial: NCT06790823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.
Trial: NCT06783569
Drug: JR8603
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles
Trial: NCT06740903
Drug: inj. lignocaine infusion @1-2 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. lignocaine infusion @ 1-2 mg/kg/h intraoperatively
Trial: NCT04975295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06153693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily (QD) for 12 weeks
Trial: NCT05972772
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250-mg capsules; Pfizer
Trial: NCT06444451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Trial: NCT06736587
Drug: DWP212525 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP212525 10mg
Trial: NCT06736587
Drug: DWP212525 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP212525 30mg
Trial: NCT06736587
Drug: DWP212525 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP212525 50mg
Trial: NCT06736587
Drug: DWP212525 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP212525 100mg
Trial: NCT06736587
Drug: DWP212525 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP212525 200mg
Trial: NCT06736587
Drug: DWP212525 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP212525 400mg
Trial: NCT06736587
Drug: DWP212525 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP212525 placebo
Trial: NCT06452134
Drug: Coenzyme Q10 100 MG Oral Tablet
RxNorm normalized name: Coenzyme Q10 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
Trial: NCT06772727
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).
Trial: NCT06452134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
Trial: NCT04580485
Drug: INCB106385
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB106385 will be administered orally QD
Trial: NCT04580485
Drug: INCMGA00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCMGA0012 will be administered IV once every 4 weeks (Q4W)
Trial: NCT06111885
Drug: Indapamide 2.5 MG
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 indapamide 2.5 mg capsule per day for 28 days
Trial: NCT06111885
Drug: Chlorthalidone 25mg
RxNorm normalized name: CHLORTHALIDONE 25MG TAB
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 chlorthalidone 25 mg capsule per day for 28 days
Trial: NCT06755502
Drug: Calcium Hydroxide, Iodoform, paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metapex as root canal filling materials
Trial: NCT06749470
Drug: Jieyu Chufan Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules, tid; 8 weeks
Trial: NCT06749470
Drug: Jieyu Chufan Capsules simulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules, tid; 8 weeks
Trial: NCT06752577
Drug: Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)
Trial: NCT04929028
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04929028
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05690841
Drug: Focal Mass Drug Administration (fMDA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by regular intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing).
Trial: NCT06766929
Drug: VSA012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT06766929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT04305327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
Trial: NCT06746831
Drug: 1:1 racemic mixture of two isomers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg R-Meth + 15 mg S-Meth
Trial: NCT04643574
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Trial: NCT06756321
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given at a dose of 250 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
Trial: NCT06751901
Drug: Neoantigen-based peptide vaccine
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Trial: NCT06780644
Drug: Triple combination cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.
Trial: NCT06780644
Drug: Triple combination cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle
Trial: NCT06781112
Drug: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with PD-1 inhibitor combined with TPF regimen, administered every 3 weeks: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and PD-1 inhibitor ( 200mg).~All patients received 3 cycles of induction therapy followed by radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment, Q3W. The cisplatin in the synchronous chemoradiotherapy regimen is administered once a week, with a dose of 40mg/m2 per dose, and the total dose of cisplatin does not exceed 100mg/m2. For patients who cannot tolerate cisplatin during synchronous radiotherapy and chemotherapy, cisplatin may not be combined.
Trial: NCT00032695
Drug: methionine
RxNorm normalized name: Methionine
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05845138
Drug: SHR-A1811 for injection ; capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 for injection; Capecitabine tablets
Trial: NCT05612074
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
Trial: NCT06335979
Drug: PIT565
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
Trial: NCT06792903
Drug: CG101 high dose + artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
Trial: NCT06792903
Drug: CG101 low dose + artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
Trial: NCT06792903
Drug: placebo + artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
Trial: NCT06359665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule twice daily
Trial: NCT05603104
Drug: Second-line Antidepressants
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT05603104
Drug: Second-line Antipsychotics
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT06582420
Drug: Standard trauma care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
Trial: NCT06792734
Drug: BTM-3566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT06769555
Drug: CM-336 BCMA/CD3 bispecific antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1. For patients achieve hematological PR or better after 2 cycles, and hematological VGPR or better after 4 cycles, the treatment regimen will change to 160mg once every 2 weeks (Q2W).
Trial: NCT06801600
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.5% dosage will be calculated and administered intrathecally as 0.4 mg/kg or 0.08 ml/kg if body weight ≤ 15 kg and 0.3 mg/kg or 0.06 ml/kg if body weight \> 15 kg
Trial: NCT06801405
Drug: antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis before percutaneous nephrostomy